Comparing Vonoprazan-Based and Esomeprazole-Based Triple Therapy for Helicobacter Pylori Infection in Adults with Dyspepsia

What this Trial Is About

Researchers are comparing two triple therapy regimens to treat Helicobacter pylori infection in adults with dyspepsia. The study aims to find out if vonoprazan-based triple therapy achieves higher eradication rates of H. pylori, improves dyspeptic symptoms better, and to identify any associated side effects compared to esomeprazole-based triple therapy. This phase 4, open-label randomized trial involves adults diagnosed with H. pylori infection confirmed by stool antigen and rapid urease tests. Participants will be randomly assigned to one of two treatment groups receiving a 14-day course of either vonoprazan-based or esomeprazole-based levofloxacin-containing triple therapy. Both regimens include amoxicillin and levofloxacin with specific dosing schedules. Medication adherence instructions will be provided. After treatment, participants with mucosal lesions identified at baseline will have follow-up endoscopy to assess healing. During the study, treatment compliance, adverse effects, and dyspeptic symptom severity will be monitored. Four weeks after completing therapy, participants will undergo repeat stool antigen testing to evaluate eradication of H. pylori. All findings including eradication rates, symptom changes, adverse events, and mucosal healing will be documented and analyzed. The total participation duration includes treatment and follow-up visits.

Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication